Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients

Li, Yang; Lai, Dan‐yun; Lei, Qing; Xu, Zhaowei; Wang, Zhen; Hou, Hongyan; Chen, Lingyun; Wu, Jiaoxiang; Ren, Yan; Ma, Ming‐liang; Zhang, Bo; Chen, Hong; Yu, Caizheng; Xue, Jun‐biao; Zheng, Yun-xiao; Wang, Xue-ning; Jiang, He‐wei; Zhang, Hainan; Qi, Huan; Guo, Shujuan; Zhang, Yandi; Lin, Xiang; Yao, Zongjie; Pang, Pengfei; Shi, Dawei; Wang, Wei; Yang, Xiao; Zhou, Jie; Sheng, Huiming; Sun, Ziyong; Shan, Hong; Fan, Xionglin; Tao, Sheng-Ce

doi:10.1038/s41423-020-00612-5

Cited by 45 publications

(57 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the AUC of the N protein was 0.995 for IgG and 0.988 for IgM, and the AUC of the S1 protein was 0.992 for IgG and 0.992 for IgM. We also found that S2–78 (1148–1159 aa) IgG is comparable to S1 IgG for COVID-19 patients, with an AUC of 0.99 for IgG and 0.953 for IgM[11].…”

Section: Discussionsupporting

confidence: 51%

COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

Lei

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the START button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn.

show abstract

Section: Discussionsupporting

confidence: 51%

COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

Lei

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…To obtain the global profile of the SARS-CoV-2 S protein-specific antibody responses of vaccinated individuals, we analyzed sera from the volunteer and convalescent groups using a peptide microarray containing 197 peptides across the S protein, and the length of the peptide is 12 amino acids, with 6 amino acids overlap for every two adjacent peptides 23 , 24 . Data for the volunteer group are presented together in Fig.…”

Section: Resultsmentioning

confidence: 99%

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Shi

et al. 2021

Cell Discov

Self Cite

View full text Add to dashboard Cite

One of the best ways to control COVID-19 is vaccination. Among the various SARS-CoV-2 vaccines, inactivated virus vaccines have been widely applied in China and many other countries. To understand the underlying protective mechanism of these vaccines, it is necessary to systematically analyze the humoral responses that are triggered. By utilizing a SARS-CoV-2 microarray with 21 proteins and 197 peptides that fully cover the spike protein, antibody response profiles of 59 serum samples collected from 32 volunteers immunized with the inactivated virus vaccine BBIBP-CorV were generated. For this set of samples, the microarray results correlated with the neutralization titers of the authentic virus, and two peptides (S1-5 and S2-22) were identified as potential biomarkers for assessing the effectiveness of vaccination. Moreover, by comparing immunized volunteers to convalescent and hospitalized COVID-19 patients, the N protein, NSP7, and S2-78 were identified as potential biomarkers for differentiating COVID-19 patients from individuals vaccinated with the inactivated SARS-CoV-2 vaccine. The comprehensive profile of humoral responses against the inactivated SARS-CoV-2 vaccine will facilitate a deeper understanding of the vaccine and provide potential biomarkers for inactivated virus vaccine-related applications.

show abstract

“…Most important landmark studies either included relatively few patients (e.g., 37 per arm) or only examined a relatively short period (e.g., 8 weeks). Additionally, different studies came to contradicting conclusion concerning waning neutralizing antibody responses in asymptomatic individuals (10)(11)(12). Therefore, we felt that the duration of protective immunity in asymptomatic individuals should be elucidated in larger cohorts and with a more informative study design.…”

Section: Introductionmentioning

confidence: 96%

Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity

Liang

Fang

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Approximately half of the SARS-CoV-2 infections occur without apparent symptoms, raising questions regarding long-term humoral immunity in asymptomatic individuals. Plasma levels of immunoglobulin G (IgG) and M (IgM) against the viral spike or nucleoprotein were determined for 25,091 individuals enrolled in a surveillance program in Wuhan, China. We compared 405 asymptomatic individuals who mounted a detectable antibody response with 459 symptomatic COVID-19 patients. The well-defined duration of the SARS-CoV-2 endemic in Wuhan allowed a side-by-side comparison of antibody responses following symptomatic and asymptomatic infections without subsequent antigen re-exposure. IgM responses rapidly declined in both groups. However, both the prevalence and durability of IgG responses and neutralizing capacities correlated positively with symptoms. Regardless of sex, age, and body weight, asymptomatic individuals lost their SARS-CoV-2-specific IgG antibodies more often and rapidly than symptomatic patients did. These findings have important implications for immunity and favour immunization programs including individuals after asymptomatic infections.

show abstract

Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients

Cited by 45 publications

References 34 publications

COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

COVID-ONE-humoral immune: The One-stop Database for COVID-19-specific Antibody Responses and Clinical Parameters

Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy

Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity

Contact Info

Product

Resources

About